Biologics

The orthopedic biomaterials market is growing as the U.S. population ages, according to a Transparency Market Research report.

The American Academy of Orthopaedic Surgeons collaborated with the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases to hold a symposium Feb. 15 through Feb. 17 at Stanford (Calif.) University on optimizing the use of biologics in orthopedic surgery.

The global spinal biologics market is expected to reach $2.4 billion by 2020, according to a MarketsandMarkets report. Here are eight companies leading the spinal biologics field.

Adam W. Anz, MD, is an orthopedic surgeon and sports medicine specialist at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine. He is the director of the Andrews Institute Regenerative Medicine Center and oversees the ATC Fellowship Program…

RTI Surgical accomplished a major milestone in April.

Here are 14 developments in spinal biologics in 2018 so far.

Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.

Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.

The global orthobiologics market is predicted to exceed $5.52 billion in 2019, according to Transparency Market Research.

DiscGenics presented results from two preclinical studies assessing its IDCT product, a homologous, allogenic, injectable cell therapy.